Galapagos (GLPG) Competitors

Blueprint Medicines (NASDAQ:BPMC) and Galapagos (NASDAQ:GLPG) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, community ranking, valuation, earnings and risk.

Which has higher earnings and valuation, BPMC or GLPG?

Galapagos has lower revenue, but higher earnings than Blueprint Medicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blueprint Medicines	$562.12M	11.66	-$67.09M	-$2.47	-41.10
Galapagos	$288.19M	6.63	$80.16M	N/A	N/A

Do institutionals & insiders believe in BPMC or GLPG?

32.5% of Galapagos shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by insiders. Comparatively, 2.9% of Galapagos shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor BPMC or GLPG?

Blueprint Medicines received 88 more outperform votes than Galapagos when rated by MarketBeat users. Likewise, 68.23% of users gave Blueprint Medicines an outperform vote while only 63.75% of users gave Galapagos an outperform vote.

Company	Underperform	Outperform
Blueprint Medicines	Outperform Votes 554 68.23%	Underperform Votes 258 31.77%
Galapagos	Outperform Votes 466 63.75%	Underperform Votes 265 36.25%

Which has more risk and volatility, BPMC or GLPG?

Blueprint Medicines has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.02, indicating that its share price is 98% less volatile than the S&P 500.

Does the media favor BPMC or GLPG?

In the previous week, Blueprint Medicines had 9 more articles in the media than Galapagos. MarketBeat recorded 14 mentions for Blueprint Medicines and 5 mentions for Galapagos. Blueprint Medicines' average media sentiment score of 1.51 beat Galapagos' score of 1.34 indicating that Blueprint Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Blueprint Medicines	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Galapagos	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend BPMC or GLPG?

Blueprint Medicines currently has a consensus target price of $126.56, suggesting a potential upside of 24.68%. Galapagos has a consensus target price of $25.33, suggesting a potential downside of 12.61%. Given Blueprint Medicines' stronger consensus rating and higher possible upside, equities research analysts plainly believe Blueprint Medicines is more favorable than Galapagos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blueprint Medicines	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.83
Galapagos	4 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Is BPMC or GLPG more profitable?

Galapagos has a net margin of 0.00% compared to Blueprint Medicines' net margin of -13.19%. Galapagos' return on equity of 0.00% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blueprint Medicines	-13.19%	-77.49%	-20.84%
Galapagos	N/A	N/A	N/A

Summary

Blueprint Medicines beats Galapagos on 12 of the 17 factors compared between the two stocks.